Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Somnomed Limited ( (AU:SOM) ) has shared an announcement.
SomnoMed Limited reported a 19.8% increase in revenue for Q2 FY25, reaching $28.5 million, with significant growth in North America and APAC regions. The company updated its FY25 guidance, forecasting revenue of approximately $105 million and EBITDA between $7 million and $9 million, despite potential growth deceleration in the latter quarters. SomnoMed also announced the appointment of Andrew Price as Director, highlighting their focus on enhancing production capacity and operational efficiency.
More about Somnomed Limited
SomnoMed Limited is a public company specializing in treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. The company offers clinically proven oral appliance therapy and supports extensive clinical research and innovation, serving more than 940,000 patients in over 20 countries.
YTD Price Performance: 3.12%
Average Trading Volume: 4,787
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $69.01M
Learn more about SOM stock on TipRanks’ Stock Analysis page.
